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Multiple layers of suppressive components including regulatory T (TReg) cells, suppressive antigen-presenting cells, and inhibitory
cytokines form suppressive networks in the ovarian cancer microenvironment. It has been demonstrated that as a major
suppressive element, TReg cells inﬁltrate tumor, interact with several types of immune cells, and mediate immune suppression
through diﬀerent molecular and cellular mechanisms.In this paper, we focus on human ovarian cancer and willdiscuss the nature
of TReg cells including their subsets, traﬃcking, expansion, and function. We will brieﬂy review the development of manipulation
of TReg cells in preclinical and clinical settings.
1.Introduction
Ovarian cancer is one of the most common and deadliest
gynecologic cancers. In 2010, 21880 new cases were diag-
nosed, and such cancer caused nearly 13850 deaths in the
UnitedStatesalone[1].Ovarian cancerusually haspoorpro-
gnosis, and most patients were diagnosed at advanced stages.
The ﬁve-year survival rate for all stages of ovarian cancer is
46% in 2010 [1]. It has been well documented that patients’
clinical outcome and ﬁve-year survival rate are positively
associated with the number of tumor-inﬁltrating lympho-
cytes(TILs) [2],and the ratioofintraepithelial CD8+ TILs to
TReg cells[3],ornegativelyassociated withtumor-inﬁltrating
TReg cells [4].
TReg cells are also known as suppressor T cells which
consist of a speciﬁc subpopulation of cells that functionally
suppress the activation of immune system and maintain
immune tolerance to self-antigens. TReg cells contain two
m a j o rs u b s e t sk n o w na sn a t u r a lT Reg cells (nTReg) and adap-
tive or induced TReg cells (iTReg). nTReg cells derived from
thymus are considered as classic TReg cells, by contrast, iTReg
cells develop in the periphery in response to self- or tumor
antigens by converting naive CD4+ T cells into TReg cells [5].
Because most tumors express self-antigens, TReg cells-medi-
ated immunosuppression is believed to be one of the major
contributors to immune evasion by tumors and becomes
the main obstacle toward successful tumor immunotherapy
[6]. In this paper, we will focus on human ovarian cancer
and discuss the nature of TReg cells including their subsets,
traﬃcking, diﬀerentiation, and proliferation and the clinical
application of manipulation of TReg cells.
2.RegulatoryT-CellSubsets
In early 1970s, Gershon and Kondo ﬁrst described the exis-
tence of thymus-derived suppressive T cells (later termed as
TReg cell) in vivo [7, 8]. After more than a decade, Sakaguchi
et al. demonstrated that CD4+ T cells expressing interleukin-
2 (IL-2) receptor alpha-chain (CD25) can be deﬁned as the
population of TReg cells with immune-suppressive activities
and maintaining immune tolerance to self-antigen [9]. Later
in 2003, Hori et al. found that the transcription factor
forkhead box P3 (Foxp3) controls the development of TReg
cells and is crucial for maintaining the immune-suppressive
function of TReg cells [10].2 Journal of Oncology
Natural TReg cells diﬀerentiate in the thymus and migrate
to periphery, which constitute 5–10% of CD4+ T cells [11–
13]. In addition, there are several subsets of TReg cells other
than CD4+CD25+Foxp3+ TReg c e l l s .G r o u xe ta l .i d e n t i ﬁ e d
another subset of TReg cells, CD4+ TR 1 cells, that suppress
antigen-speciﬁc immune responses by producing high levels
of IL-10 [14]. In addition to CD4+ TReg,C D 8 + suppressive
T cells have been found playing an important role in the
regulation of autoimmune disease [7, 15]. CD8+ suppressive
T cells now refered to as CD8+ TReg cells are characterized as
CD8+CD25+,C D 8 +CD122+,o rC D 8 +CD45RClow TReg cells,
which compriseless than 1%ofperipheralCD8+ Tcells[15].
Th3 TReg cells have similar immune-suppressive function;
however, in contrast to natural TReg cells, Th3 exerts its
suppressive capacity independent of cell membrane contact
but mainly bases on the action of self-produced cytokine
TGFβ [16].
3.RegulatoryT-CellTrafﬁcking
TReg cells consist of ∼10% of peripheral CD4+ T cells char-
acterized as CD4+CD25+FOXP3+ T cells, which is important
for the control of autoimmune reaction [9, 11]. Dysregula-
tion of TReg can cause autoimmune diseases [17]a n dm a y
contribute to tumor-initiated immune evasion [18]. As de-
monstrated by in vivo mouse model, the deletion of TReg
cellsresultsintumorrejection[19].However,thesuppressive
capacity of TReg cells is also determined by the ratio of
TReg cells to eﬀector T cells [3]. A high CD8+/TReg ratio is
associated with favorable prognosis and improved survival
[3, 20]. It has been reported that many human cancers are
associated with high frequency of TReg cells in the circulation
or in the tumor tissues, including ovarian cancer [4], lung
cancer [21], breast cancer [22], liver cancer [23], head and
neckcancer[24], and lymphoma [25]. These increased levels
of TReg cells are linked to high death hazard and poor
survival, while the depletion of tumor-inﬁltrated TReg cells
and the blockade of TReg traﬃcking to tumors enhance anti-
tumor immune response [4, 26].
CCR4 and its binding partners CCL22 and CCL17 are
believed to be the most predominant axis in chemokine-
mediated selective TReg traﬃcking to the tumors. Iellem et al.
have proﬁled chemotactic responses and chemokine recep-
tors expression of human TReg cells and found that TReg cells
speciﬁcally express chemokine receptors CCR4 and CCR8
[27]. Chemokine CCL22, the ligand for CCR4, preferentially
attracts activated-antigen-speciﬁc T cells to dendritic cells
[28, 29]. It has also been shown that human ovarian cancer
cells and tumor-associated microphages produce chemokine
CCL22, which mediates TReg cells traﬃcking to tumor [4].
Blockade of CCL22 in vivo signiﬁcantly reduces human
TReg cells traﬃcking to tumors in ovarian carcinoma [4].
This chemokine-mediated TReg traﬃcking has been also
observed in other types of cancer, such as gastric cancer
[30], Hodgkin’s lymphoma [31], and breast cancer [32].
Interestingly, in gastric cancer, CCL22 and CCL17 seem both
important torecruitTReg cellstothetumorsasdemonstrated
by in vivo study as well as in vitro migration assay, and
the levels of CCL22 and CCL17 within tumors are correlated
totheincreasedlevelsofTReg cellsinearlygastriccancer[33].
Besides CCR4 chemokine axis, CCR5/CCL5 axis may
also selectively recruit TReg c e l l st ot h et u m o r s .U s i n gh u m a n
pancreatic adenocarcinoma and murine pancreatic tumor
model, it has been found that CCR5 is highly expressed
in TReg cells, while tumor cells produce elevated amount
of CCL5, and disruption of CCR5/CCL5 chemokine axis
blocks TReg cells migration and reduces tumor growth [34].
In addition, CCL20 chemokine shows high aﬃnity to CCR6




CD4+CD25+ TReg cells are generated in the thymus. Papi-
e r n i ke ta l .f o u n dt h a tp e r i p h e r a lT Reg migrates from the
thymus and appears in the periphery as early as 10th day of
life [36]. They also found that CD4+CD25+ TReg cells diﬀer-
entiationistotallydependentonIL-2,becauseIL-2knockout
mice do not develop CD4+CD25+ TReg in vivo [36]. Further
evidences have been provided from the studies on irradiated
rat model [37]. In this study, autoimmune diseases were
induced in rats by thymectomy and irradiation; however the
xenograft transfer of CD4+ T cells from normal rats can
abrogate the autoimmune responses. These observations
suggest that normal thymus-derived T cells have immune
suppressive functions and thus prevent autoimmunity [37].
In another model system, adoptive transfer of thymocytes
or peripheral T cells depleted of CD4+CD25+ TReg cells
causes autoimmune diseases in mice, which provides further
evidences of thymic origin of TReg c e l l sa n dt h e i rp e r i p h e r a l
existence [38].
However, there is little known about the comprehensive
requirements for thymic TReg development. Although there
are several arguments about how and what stromal compo-
nents are involved in thymic TReg cell diﬀerentiation, thymic
stromal cells, including cortical and medullary thymic epi-
thelial cells and dendritic cells (DCs), contribute to TReg cells
diﬀerentiation and selection [38]. Jordan et al. used TCR-
transgenic mice which express the receptor recognizing spe-
ciﬁc self-antigen and found that thymocytes bearing a TCR
with high aﬃnity to a speciﬁc self-antigen undergo selection
and become CD4+CD25+ TReg cells when interacting with
a single self-antigen, but thymocytes bearing TCR with low
aﬃnity do not undergo selection [39].
In addition to thymus, TReg can also be generated in the
periphery. For instance, tumor microenvironment favors the
induction and diﬀerentiation of TReg cells, and that has been
extensivelystudiedforseveralyears[40].Inthetumormicro-
environment, DC diﬀerentiation and function were sup-
pressed by tumor-associated factors IL-10, VEGF, and TGFβ,
resulting in immature/dysfunctional DC [6]. Dysfunctional
DC directly contributed to the induction ofIL-10-producing
TReg cells in vivo in human and in vitro [41, 42]. Tumor-
associated plasmacytoid DC also induced IL-10+ TReg gener-
ation [43, 44]. Tumor can convert DC into TGFβ-producingJournal of Oncology 3
immature DC, which selectively promotes TReg proliferation
in TGFβ-dependent manner [45].
CD4+CD25+ TReg cells can also be converted from pe-
ripheral na¨ ıve CD4+CD25− T cells by the action of TGFβ.
Tumor microenvironment contains high levels of TGFβ
which might mediate tumor-associated TReg cells conversion
[46].
5.TargetingRegulatoryTCells
5.1. TReg Cell Depletion. In the mouse model, depletion of
CD4+CD25+ TReg cells using anti-CD25 antibody causes tu-
mor regression, which correlated to the reduced number of
TReg cells [18, 47]. Using the recombinant IL-2 diphtheria
toxin conjugate DAB(389)IL-2 (also known as denileu-
kin diftitox and ONTAK), Dannull et al. demonstrated
that DAB(389)IL-2 was capable of selectively eliminating
CD25+ TReg cellsfromthePBMCsofcancerpatientswithout
inducing toxicity on other cellular subsets, and DAB(389)IL-
2-mediated TReg depletion enhanced anti-tumor immune
responses and signiﬁcantly reduced the number of TReg cells
present in the blood of cancer patients [48]. Daclizumab
(also known as Zenapex) and Basiliximab (also called Sim-
ulect) are monoclonal antibodies against CD25 [49, 50], and
the administration of Daclizumab in patient with metastatic
breast cancer enhanced anti-tumor immunity [51].
CytotoxicT-lymphocyte-associated antigen 4(CTLA4)is
constitutively expressed and restricted to CD4+CD25+ TReg
cells among all CD4+ cells, and the immune-suppressive
function of TReg is mediated by CTLA4 signaling [52, 53].
CTLA4 binds to inhibitory B7 members on APC and trans-
mits an inhibitory signal to T cells. In vivo administration
of anti-CTLA4 antibody resulted in tumor rejection includ-
ing preestablished tumors [54]. Periodic infusions of anti-
CTLA4 antibody in previously vaccinated patients with can-
cer created clinically eﬀective antitumor immune response
[55]. Patients with metastatic melanoma showed improved
antitumor immunity and tumor regression by blockade of
CTLA-4 together with peptide vaccination [56].
Glucocorticoid-induced tumor necrosis factor (TNF) re-
ceptor family-related protein (GITR or DTA-1) is predom-
inantly expressed on the surface of TReg cells. An agonistic
anti-GITR antibody administration in mice can abrogate
TReg-mediated immune suppression and enhance eﬀective
anti-tumor immunity in vivo [57,58]. Inaddition, treatment
with anti-GITR antibody in B16 mice elicited immune
response and rejected tumor [59]. However GITR is not ex-
clusivelyexpressed on TReg cell; it isalso expressed by various
CD4+ T cells and others. Therefore, the clinical therapeutic
relevance of GITR blockade and its side eﬀects on potential
deﬁcits of other eﬀective immune cells remain to be deter-
mined.
OX40 (CD134) also belongs to TNF receptor family and
expressed on activated T cells. Both na¨ ıve and activated TReg
express OX40. Similar to GITR, triggering OX40 by an ago-
nisticantibodyagainstOX40reducesTReg-mediatedimmune
suppression and restores eﬀector T-cell function both in
vivo and in vitro [60]. It has been also shown that OX40 is
necessary for TReg development, homeostasis, and immune-
suppressive activity. However, stimulation of OX40 signal in
na¨ ıve T cells can abrogate TReg-mediated suppression [61].
Clinical relevance of the depletion of TReg cells has been
further conﬁrmed by the treatment of cyclophosphamide
(CY) in the patients bearing tumor. Cyclophosphamide is
a nitrogen mustard alkylating agent that mediates DNA
crosslinking. Low dose of CY administration improved pa-
tients’ immune responses by reducing the number of TReg
cells and by decreasing the suppressive activity of TReg
cells [62]. Eﬀects of TReg depletion on anti-tumor immune
responses were further investigated by the study on B16
melanomas mouse model [63]. Other immunosuppressants
like cyclosporine A (CSA) and azathioprine might also in-
hibit TReg cells generation[64, 65]. For instance, high dose of
CSA abrogates TReg cell generation; by contrast, low dose of
CSA can promote TReg cell development [64]. It is therefore
important to determine whether lowdose of those agents can
improve antitumor immunity in patients.
5.2. Targeting TReg Traﬃcking. O u rg r o u ph a sd e m o n s t r a t e d
that human ovarian cancer cells and tumor-associated
macrophage (TAM) produced chemokine CCL22, the ligand
for CCR4 which functionally expressed on tumor TReg cells,
mediating TReg cells traﬃcking to the tumor and ascites, and
the blockade of CCL22 abrogated TReg cells migration [4].
It has been demonstrated that chemokine receptor CCR4 is
selectively expressed by TReg cells, and the CCR4 and CCR4-
a s s oci a t ec h em oki n esa xi si son eofth em os tdes cri bedtum or
TReg recruitment axes [66]. The administration of anti-
CCR4 antibody eﬀectively depletes CCR4+ T cells and in-
hibits TReg cells migration in Hodgkin lymphoma [31].
Furthermore, the signiﬁcant correlation between CCL17 or
CCL22 chemokines and the number of tumor-inﬁltrating
TReg cells was found in patients with neoplastic meningitis
and gastric cancer [30, 33]. CCL5 and CCL20 chemokines
are also involved in TReg traﬃcking, and that blockade of
those chemokines reduces TReg cells traﬃcking and inhibits
tumorgrowth[34,35].Wehaveshown thatCXCL12/CXCR4
axismediatedTReg traﬃckingtobonemarrow[67].Recently,
a study has demonstrated that blockade of CXCR4 by a
selective antagonist resulted in the signiﬁcant reduction of
intratumoral TReg cells, which was associated with greatly
increased antitumor immunity and an improved survival in
an immunocompetent mouse model of ovarian cancer [68].
5.3. Targeting TGFβ Signaling Pathway. TGFβ is implicated
in TReg diﬀerentiation, conversion, and function. It is
thought that blockade of TGFβ signaling pathway may alter
TReg phenotype and function and in turn enhances antitu-
mor immunity [6]. In addition to TReg cells, ovarian carci-
noma cells can also produce TGFβ [69]. Notably, TGFβ is
not only important for TReg cell functional integrity, but also
inhibits the proliferation and functional diﬀerentiation of T
lymphocytes, NK cells, and macrophages [46, 70]. This may
induceT-cellunresponsivenesstoTCRstimulation,failureto
produce Th1 cytokines, and production of additional TGFβ
[46]. TGFβ signaling may also be crucial for tumor cell4 Journal of Oncology
transformation. Therefore, targeting TGFβ signaling may be
therapeutically meaningful. TGFβ inhibitor AP 12009 was
tested in a Phase I/II clinical trial for advanced pancreatic
cancerand othermalignancies [71]. LY2109761, an inhibitor
ofTGFβI/IIreceptors,cansuppresspancreaticcancermetas-
tases [72]. In a preclinical model, we have shown that
anti-TGFβ can reduce TReg cells in tumors and tumor-
draining lymph nodes. This eﬀect is enhanced by B7-H1
blockade [73]. Nonetheless, it is clear that blocking TGFβ
signaling may aﬀect TReg compartment. However, as TGFβ
is implicated in multiple layers of biological activities, the
ultimate clinical therapeutic eﬃciency and side eﬀects of
TGFβ signaling blockade remain to be investigated.
5.4.TargetingInhibitoryB7FamilyMembers. Theexpression,
regulation, functional, and clinical relevance of inhibitory
B7 family members have been reviewed elsewhere [74].
Human ovarian cancer and cancer-associated myeloid
antigen-presenting cells express high levels of B7-H1 (PD-
L1), which are negatively associated with patient survival
[74, 75]. Patients with high expression of B7-H1 had a
signiﬁcantly poor prognosis compared to the patients with
low expression of B7H1 [76]. B7-H1 expression was also
found inversely correlated to the intraepithelial CD8+ Tl y m -
phocyte count, indicating that B7-H1 on tumor cells
may suppress antitumor CD8+ T cells [76]. The receptor,
programmed death 1 (PD-1),is expressed on activated T-cell
subsets, antigen-speciﬁc CD8+ T cells [77], and TReg [78].
Interestingly, B7-H1/PD-1 has been reported to be involved
in the development of induced TReg cells [79]. Therefore,
targeting B7-H1/PD-1 signaling pathway may reduce TReg
development and function. As anti-PD-1 is in clinical appli-
cation to treat patients with melanoma, renal cell carcinoma,
and other cancers, further mechanistic studies on these pa-
tients will determine if the eﬀects of anti-PD-1 on TReg cells
are mechanistically and clinically relevant.
In addition to B7-H1,human ovarian cancer and cancer-
associated myeloid antigen-presenting cells also express high
levels of B7-H4 (B7x, B7s1), which are negatively associated
with patient survival [74, 80, 81]. Interestingly, TReg cells can
induce IL-10 expression by APCs and indirectly stimulate
B7-H4 expression on APCs and convey suppressive activity
to APCs [74, 80, 81]. Thus, it is tempting to speculate that
blocking B7-H4 signaling pathway may disable the suppres-
sive eﬀects of TReg cells on APCs. Notably, as the receptor for
B7-H4 has not been identiﬁed, B7-H4 signaling is much less
understood in both mouse and human system. Nonetheless,
studies on ovarian cancer patients and preclinical cancer
models suggest that interruption of B7-H4 signaling may
lead to improved antitumor T-cell response and decreased
TReg suppressive function.
6.Conclusions
TReg cells inﬁltrate tumor including ovarian cancer. Their
phenotype, traﬃcking mechanism, suppressive activity, and
clinical relevance have been deﬁned in human cancer. How-
ever, recent evidence indicates that TReg cells may not be
stable and are subject to environmental regulation. In this
regard, it remains poorly understood how TReg cells evolve
in human tumor microenvironment. Although their action
mode of mechanisms has been investigated in many diﬀerent
physiological and pathological scenarios, the key suppressive
mechanisms may be diﬀered in diﬀerent tumors or/and in
diﬀerent stages. Therefore, further patient-oriented studies
are essential for dissecting TReg cell biology. Nonetheless,
targeting TReg cells or/and reprogramming TReg cells is an
important strategy to treat patients with cancer. It is sug-
gested that combinatorial therapy by incorporating TReg ma-
nipulation may be ideal direction to developnovel therapeu-
tic regimen to eﬃciently treat patients with cancer.
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